These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25523428)

  • 1. Predicting progression from cognitive impairment to Alzheimer's disease with the Disease State Index.
    Hall A; Mattila J; Koikkalainen J; Lötjonen J; Wolz R; Scheltens P; Frisoni G; Tsolaki M; Nobili F; Freund-Levi Y; Minthon L; Frölich L; Hampel H; Visser PJ; Soininen H
    Curr Alzheimer Res; 2015; 12(1):69-79. PubMed ID: 25523428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease.
    Hall A; Muñoz-Ruiz M; Mattila J; Koikkalainen J; Tsolaki M; Mecocci P; Kloszewska I; Vellas B; Lovestone S; Visser PJ; Lötjonen J; Soininen H; ; ;
    J Alzheimers Dis; 2015; 44(1):79-92. PubMed ID: 25201784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
    Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
    Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olfactory identification in amnestic and non-amnestic mild cognitive impairment and its neuropsychological correlates.
    Vyhnalek M; Magerova H; Andel R; Nikolai T; Kadlecova A; Laczo J; Hort J
    J Neurol Sci; 2015 Feb; 349(1-2):179-84. PubMed ID: 25614440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study.
    Damian M; Hausner L; Jekel K; Richter M; Froelich L; Almkvist O; Boada M; Bullock R; De Deyn PP; Frisoni GB; Hampel H; Jones RW; Kehoe P; Lenoir H; Minthon L; Olde Rikkert MG; Rodriguez G; Scheltens P; Soininen H; Spiru L; Touchon J; Tsolaki M; Vellas B; Verhey FR; Winblad B; Wahlund LO; Wilcock G; Visser PJ
    Dement Geriatr Cogn Disord; 2013; 36(1-2):1-19. PubMed ID: 23651945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of odors, faces, cities and naming of objects in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer´s disease: a longitudinal study.
    Tahmasebi R; Zehetmayer S; Pusswald G; Kovacs G; Stögmann E; Lehrner J
    Int Psychogeriatr; 2019 Apr; 31(4):537-549. PubMed ID: 30236169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative evaluation of disease progression in a longitudinal mild cognitive impairment cohort.
    Runtti H; Mattila J; van Gils M; Koikkalainen J; Soininen H; Lötjönen J;
    J Alzheimers Dis; 2014; 39(1):49-61. PubMed ID: 24121959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study.
    Kida J; Nemoto K; Ikejima C; Bun S; Kakuma T; Mizukami K; Asada T
    J Alzheimers Dis; 2016; 51(2):405-15. PubMed ID: 26890740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
    Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
    Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns.
    Lerch O; Ferreira D; Stomrud E; van Westen D; Tideman P; Palmqvist S; Mattsson-Carlgren N; Hort J; Hansson O; Westman E
    Alzheimers Res Ther; 2024 Jul; 16(1):153. PubMed ID: 38970077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information.
    Steenland K; Zhao L; John SE; Goldstein FC; Levey A; Alvaro A;
    J Alzheimers Dis; 2018; 63(4):1383-1393. PubMed ID: 29843232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.
    Rhodius-Meester HF; Koikkalainen J; Mattila J; Teunissen CE; Barkhof F; Lemstra AW; Scheltens P; Lötjönen J; van der Flier WM
    J Alzheimers Dis; 2016; 50(1):261-70. PubMed ID: 26577521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The free and cued selective reminding test for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: A prospective longitudinal study.
    Lemos R; Marôco J; Simões MR; Santiago B; Tomás J; Santana I
    J Neuropsychol; 2017 Mar; 11(1):40-55. PubMed ID: 26058529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subjective Spatial Navigation Complaints - A Frequent Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease.
    Cerman J; Andel R; Laczo J; Vyhnalek M; Nedelska Z; Mokrisova I; Sheardova K; Hort J
    Curr Alzheimer Res; 2018; 15(3):219-228. PubMed ID: 29165083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years.
    Albert M; Zhu Y; Moghekar A; Mori S; Miller MI; Soldan A; Pettigrew C; Selnes O; Li S; Wang MC
    Brain; 2018 Mar; 141(3):877-887. PubMed ID: 29365053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer's dementia and vascular dementia.
    Jungwirth S; Zehetmayer S; Hinterberger M; Tragl KH; Fischer P
    Int Psychogeriatr; 2012 Jun; 24(6):959-66. PubMed ID: 22300486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild cognitive impairment due to alzheimer disease is less likely under the age of 65.
    Shin S; Kim JH; Cho JH; Kim GS; Choi SA; Lee JH;
    Alzheimer Dis Assoc Disord; 2015; 29(1):26-31. PubMed ID: 24759547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.